PhD Studentship: New pharmacological tools for targeting P2X receptors in cancer

University of East Anglia

Norwich

On-site

GBP 20,000 - 24,000

Full time

14 days+

A complete application in a minute

Tailored resume and cover letter, ready to send.

Get past ATS filters

Benefits offered by this job

Funding for UK applicants
Annual stipend £21,805

Job summary

The University of East Anglia invites applications for a PhD project exploring P2X7 and P2X4 receptors in cancer biology. The project combines RNAseq, qPCR, and CRISPR/Cas9 gene editing to understand receptor expression and function under different conditions.

This funded studentship, available to UK applicants, covers home tuition fees and an annual stipend of 21,805 pounds, for a 3-year period. Start date is 1 October 2027.

Qualifications

  • 2:1 in Pharmacology, MPharm, Biomedicine, Biomedical Science or Biological Sciences.
  • Full-time PhD project with UK funding for three years.
  • Skills include cell culture, molecular biology, gene editing and pharmacology.

Responsibilities

  • Characterise splice variant expression of P2X7 and P2X4 across cancer cell lines.
  • Generate P2X7 and P2X4-null cancer cells using CRISPR/Cas9 editing.
  • Test dual antagonists of P2X7/P2X4 in in vitro cancer cell survival assays.

Skills

Cell culture
Molecular biology
Gene editing
Pharmacology

Education

2:1 in Pharmacology, MPharm, Biomedicine, Biomedical Science, Biological Sciences

Tools

CRISPR/Cas9
RNAseq data analysis
qPCR

Job description

About the Project

Primary Supervisor - Dr Leanne Stokes

There is a growing literature documenting the exploitation of ion channels by cancer cells. P2X receptors are ligand-gated ion channels (P2X1-7) activated by the extracellular signalling molecule ATP. Concentrations of ATP are known to be high within tumour microenvironments potentially driving cellular adaptations and exploiting downstream signalling associated with P2X receptors. This project will undertake two main lines of investigation; i) to characterise the expression of important P2X receptors and their variants within cancer cells under different conditions, and ii) to determine the benefit of blocking various P2X receptors (either individually or through dual antagonism) to cancer cell growth and survival.

Aberrant splicing events are common within cancer and novel splice isoforms have the potential to be neo-antigens (e.g. targets for immunotherapy or markers for diagnostic/prognostic purposes). At least 18 splice variants of P2X7 have been described but very little is known about their expression levels and functionality. Nothing is known about P2X4 variants as yet. We will explore RNAseq data from public databases and together with quantitative PCR data, we will assemble this information. Our recent work has discovered compounds that can act as dual antagonists of P2X7 and P2X4 receptors and we will compare their efficacy to individual blockade of either P2X7 or P2X4.

The aims of the project are to 1) characterise splice variant expression of P2X7 and P2X4 receptors across a range of cancer cell lines and conditions, 2) generate P2X7 and P2X4-null cancer cells using CRISPR/Cas9 gene editing to further understand how these ion channels contribute to cancer cell biology, and 3) testing of dual antagonists of P2X7/P2X4 in in vitro cancer cell survival and growth assays. Skills developed: cell culture, molecular biology, gene editing and pharmacology plus transferable skills. This project would suit a graduate from Biomedical Science or Pharmacology.

Entry Requirements

The standard minimum entry requirement is 2:1 in Pharmacology, MPharm, Biomedicine, Biomedical Science, Biological Sciences

Mode of Study

Full-time

Start Date

1 October 2027

Additional Funding Information

This PhD project is in a competition for a Faculty of Science funded studentship. Funding is available to UK applicants and comprises ‘home’ tuition fees and an annual stipend for 3 years. The current UEA / institutional PhD stipend rate is £21,805 and will be subject to any agreed inflationary uplift for 2027/28.

Get your free, confidential resume review.

or drag and drop your file here.

Similar jobs

Similar jobs worth comparing

PhD: Targeting P2X Receptors in Cancer with Antagonists
PhD: Targeting P2X Receptors in Cancer with Antagonists

University of East Anglia • Norwich

On-site
GBP 20,000 - 24,000
Funding for UK applicants
Annual stipend £21,805
PhD Studentship: Machine Learning-Guided Engineering of Next-Generation Cancer Therapeutics
PhD Studentship: Machine Learning-Guided Engineering of Next-Generation Cancer Therapeutics

University of East Anglia • Norwich

On-site
GBP 20,000 - 24,000
Research Associate in Cancer Biology
Research Associate in Cancer Biology

University of Bristol • West of England

On-site
GBP 41,000 - 46,000
PhD Studentship: How to build an immune receptor: AI-led protein design for engineering disease resistance
PhD Studentship: How to build an immune receptor: AI-led protein design for engineering disease resistance

University of East Anglia • Norwich

On-site
GBP 22,000 - 27,000
Tuition fees paid
Stipend £21,805 per year
RTSG £5,000 per year
AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for Oncology: Harnessing Ubiquitin-independent Pathways
AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for Oncology: Harnessing Ubiquitin-independent Pathways

University of Cambridge • Cambridge

On-site
GBP 18,000 - 21,000
PhD Studentship: Chemical Biology to target bacteria: Inhibiting bacterial growth by controlling cell division protein interactions
PhD Studentship: Chemical Biology to target bacteria: Inhibiting bacterial growth by controlling cell division protein interactions

University of East Anglia • Norwich

On-site
GBP 20,000 - 24,000
Fully funded PhD stipend
Tuition fees covered
Professional development programme
PhD Studentship in Development of Pancreatic Tumour Treating Field System
PhD Studentship in Development of Pancreatic Tumour Treating Field System

RFCSR • Plymouth

On-site
GBP 18,000 - 21,000
Fully funded PhD studentship
Stipend in line with UKRI rates
FSE PhD President's Doctoral Scholarship: Sensing BRCA2 Loss: Synthetic Antibodies for Precision Prostate Cancer Treatment
FSE PhD President's Doctoral Scholarship: Sensing BRCA2 Loss: Synthetic Antibodies for Precision Prostate Cancer Treatment

The University of Manchester • Manchester

On-site
GBP 20,000 - 24,000
CASE PhD Studentship. Developing selective PDE4B-targeting PROTACs
CASE PhD Studentship. Developing selective PDE4B-targeting PROTACs

RSEQ • Lancaster

Hybrid
GBP 21,000 - 25,000
CASE Studentship
AstraZeneca placement
Industry collaboration
PhD Studentship: Decoding the rules of human gene interaction networks using combinatorial functional genomics
PhD Studentship: Decoding the rules of human gene interaction networks using combinatorial functional genomics

University of Exeter • Exeter

On-site
GBP 20,000 - 24,000